



Published in final edited form as:

Genet Med. 2022 October ; 24(10): 2187–2193. doi:10.1016/j.gim.2022.07.012.

Biallelic variants in *ADAMTS15* cause a novel form of distal arthrogyrosis

Felix Boschann^{1,2,*}, Muhsin Ö. Cogulu^{3,*}, Davut Pehlivan^{4,5,6}, Saranya Balachandran^{7,8}, Pedro Vallecillo-Garcia⁹, Christopher M. Grochowski⁴, Nils R. Hansmeier^{1,2,10}, Zeynep H. Coban Akdemir¹¹, Cesar A. Prada-Medina², Ayca Aykut¹⁰, Björn Fischer-Zirnsak^{1,2}, Simon Badura¹³, Burak Durmaz³, Ferda Ozkinay¹⁰, René Hägerling^{1,2,11}, Jennifer E. Posey⁴, Sigmar Stricker⁹, Gabriele Gillessen-Kaesbach⁷, Malte Spielmann^{7,8}, Denise Horn¹, Knut Brockmann¹³, James R. Lupski^{4,5}, Uwe Kornak^{1,2,14,§}, Julia Schmidt^{7,14}

¹Institute of Medical Genetics and Human Genetics, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

²RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany

³Department of Pediatric Genetics, Faculty of Medicine, Ege University, Izmir, Turkey

⁴Department of Molecular and Human Genetics, Baylor College of Medicine, Houston TX, USA

⁵Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX, USA

⁶Section of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

⁷Institute of Human Genetics, University of Lübeck, Lübeck, Germany

⁸Institute of Human Genetics, Kiel University, Kiel, Germany

⁹Institute of Biochemistry, Free University Berlin, Berlin, Germany

¹⁰Department of Medical Genetics, Faculty of Medicine, Ege University, Izmir, Turkey

§= corresponding author: Corresponding author's address: Uwe Kornak, Institute of Human Genetics, University Medical Center Göttingen, Heinrich-Düker-Weg 12, 37073 Göttingen, Germany, uwe.kornak@med.uni-goettingen.de.

*= these authors contributed equally to this work

Author contributions

Conceptualization: D.P., G.G.-K., J.E.P., J.R.L., J.S., M.Ö.C., U.K. Data curation: D.P., F.B., J.S., M.Ö.C., M.S., R.H., S.Bad., S.S., U.K. Formal analysis: C.A.P.-M., D.P., F.B., J.S., S.S., U.K. Investigations: A.A., B.D., C.A.P.-M., C.M.G., M.S., N.R.H., P.V.-G., S.Bad., S.Bal. Visualization: C.M.G., F.B., J.S., M.S., N.R.H., P.V.-G., S.Bal. Writing—original draft: D.P., F.B., J.R.L., J.S., U.K. Writing—review & editing: C.M.G., B.D., D.P., D.H., F.B., F.O., J.R.L., J.E.P., J.S., K.B., M.Ö.C., M.S., R.H., S.S., U.K. Supervision: D.P., G.G.-K., J.R.L., J.S., K.B., M.Ö.C., R.H., S.S., U.K.

Conflict of Interest

J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Genetics Center, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, genomic disorders, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic and genomic testing conducted at Baylor Genetics (BG); J.R.L. serves on the Scientific Advisory Board (SAB) of BG.

Ethics declaration

This study adheres to the principles in the Declaration of Helsinki. Permission for the study was obtained from the Ethics Committee of the University Medical Center Göttingen (proposal no. 10/4/21 Ü). Written informed consent was obtained from all participants including consent for publication of photographs. Consent forms are archived and available upon request.

¹¹BIH Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

¹²Department of Epidemiology, Human Genetics & Environmental Sciences, UTHealth School of Public Health, Houston, TX, USA

¹³Interdisciplinary Pediatric Center for Children With Developmental Disabilities and Severe Chronic Disorders, Department of Pediatrics and Adolescent Medicine, University Medical Center Göttingen, Göttingen, Germany

¹⁴Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany

Abstract

Purpose: We aimed to identify the underlying genetic cause for a novel form of distal arthrogyposis.

Methods: Rare variant family-based genomics, exome and disease-specific panel sequencing were used to detect *ADAMTS15* variants in affected individuals. *Adamts15* expression was analyzed at the single-cell level during murine embryogenesis. Expression patterns were characterized by *in situ* hybridization and RNAscope.

Results: We identified homozygous rare variant alleles of *ADAMTS15* in five affected individuals from four unrelated consanguineous families, presenting with congenital flexion contractures of the interphalangeal joints and hypoplastic or absent palmar creases. Radiographic investigations showed physiological interphalangeal joint morphology. Additional features included knee, Achilles tendon, and toe contractures, spinal stiffness, scoliosis, and orthodontic abnormalities. Analysis of mouse whole-embryo single-cell sequencing data revealed a tightly regulated *Adamts15* expression in the limb mesenchyme between embryonic stages E11.5 and E15.0. A perimuscular and peritendinous expression was evident by *in situ* hybridization in the developing mouse limb. In accordance, RNAscope analysis detected a significant co-expression with *Osr1*, but not with markers for skeletal muscle or joint formation.

Conclusion: In aggregate, our findings provide evidence that rare biallelic recessive trait variants in *ADAMTS15* cause a novel autosomal recessive connective tissue disorder resulting in a distal arthrogyposis syndrome.

Keywords

distal arthrogyposis; ADAMTS15; exome sequencing; connective tissue

Introduction

The distal arthrogyposes (DA) are characterized by contractures involving two or more body parts, primarily affecting the wrists, hands, ankles and feet.¹ The contractures can vary in severity, but usually are not progressive and do not affect previously unaffected joints.² To date, more than ten DA types and 15 associated genes have been identified.^{1,3} Most DA types are caused by heterozygous pathogenic variants in genes encoding sarcomeric

components of skeletal muscle fibers.⁴ Besides this “myopathic” forms, arthrogyrosis can be categorized etiologically into “neuropathic” or “connective tissue” associated types.⁵

The ADAMTS/L superfamily comprises 19 metalloproteases and seven structurally related glycoproteins (i.e., ADAMTS-like proteins) that play prominent roles in connective tissue homeostasis.⁶ The ADAMTS proteases share a similar structure containing a conserved N-terminal protease domain and a modular organized C-terminal ancillary domain, which mediates binding to extracellular matrix (ECM) components.⁷ While most of these enzymes participate in cleaving various substrates, such as procollagen, versican and aggrecan, some proteases appear to function more as ADAMTS-like proteins and are implicated in microfibril assembly and ECM regulating pathways such as TGF- β - and BMP-signaling.^{6,7} To date, eight members of the superfamily have been linked to different autosomal recessive (AR) disease traits.⁸ Using exome sequencing (ES) and disease-specific panel analysis, we detected biallelic variants in *ADAMTS15* (HGNC:16305, MIM 607509), in five affected individuals from four independent consanguineous families with congenital distal contractures. *ADAMTS15* is located on chromosome 11q24.3. The canonical transcript (ENST00000299164.3; NM_139055.3) consists of 8 exons and encodes a 950 residue protein that presumably acts as an extracellularly activated protease that hydrolyses versican (versicanase).⁹ Detailed knowledge about the function and tissue-specific expression is lacking.

Our data implicate biallelic *ADAMTS15* pathogenic variants as causative for a Mendelian disease trait involving distal contractures. Given our RNA data, we hypothesize that *ADAMTS15* plays a critical role in perimuscular connective tissue and tendon development, which is disturbed in distal arthrogyrosis caused by *ADAMTS15* loss of function.

Methods and Materials

Parental consent was obtained for all clinical and molecular studies in this report and for the publication of clinical photographs. Next generation sequencing (NGS) was performed at Charité-Universitätsmedizin Berlin (Individual 1: Trio-ES and Individual 5: Trio-ES), Baylor College of Medicine (Individual 3: Single-ES) and University Medical Center Göttingen (Individual 4: Panel sequencing). Given the virtual absence of *ADAMTS15* expression in all typical cell lines and accessible human tissues (for an overview consult <https://www.proteinatlas.org/ENSG00000166106-ADAMTS15>), we investigated the cell types expressing the gene during embryogenesis at the single-cell level using the Mouse Organogenesis Cell Atlas (MOCA).¹⁰ Furthermore, we performed droplet digital PCR (ddPCR), *in situ* hybridization, and RNAscope for further functional characterization of *Adamts15* expression. Further details can be found in Supplemental Material.

Results

Clinical data

All five affected participants displayed similar distal congenital contractures of the fingers and toes (Fig. 1c). The fingers were bent in the proximal interphalangeal joints (PIPs), while the distal parts were tapered and had hypoplastic or absent flexion creases. The

musculature of the hands was partially atrophic, and all had a mild appearance of fetal finger pads and clinodactyly of the fifth finger. Further clinical findings included contractures of knee, Achilles tendon and ankle (4/5), spine involvement (kyphoscoliosis and/or spinal stiffness) (4/5), and orthodontic features (small mouth, dental crowding, missing teeth or arched palate) (4/5). No involvement of the central nervous system or other organs was noted, and radiographs of the hands and feet excluded a primary involvement of the bones or joints (Fig. 1c). Detailed clinical descriptions are available in the Supplemental Material, summarized as Table S1, and compared to overlapping entities in Table S2.

Molecular findings

Using ES, rare variant family-based genomics, and disease-specific panel analyses, we identified four rare homozygous variants in *ADAMTS15* (NM_139055.3). The variant c.123C>G, p.(Tyr41*) is predicted to result in a premature termination codon (PTC) in the first exon. On the cDNA level (synthesized from RNA extracted from patient-derived fibroblasts), the variant c.1903-2A>G was shown by droplet digital PCR (ddPCR) and Sanger sequencing of an RT-PCR amplicon to lead to a complete skipping of exon 7 (r.1903_2078del), which is predicted to result in a frameshift and premature stop of translation p.(Val635Alafs*30) (Fig. S1). The missense variants c.2281G>A, p.(Gly761Ser) and c.2715C>G, p.(Cys905Trp) affect highly conserved amino acids within the ADAMTS spacer 1 and thrombospondin type 1 domain, respectively (Fig. S2). All variants except c.2281G>A are not found in gnomAD. The location of the identified variants and bioinformatic *in silico* predictions are summarized in Fig. 1b and Table S3. Segregation analysis is provided in Fig. S3.

Calculations for individuals 1, 2 and 5 revealed large absence of heterozygosity (AOH) blocks surrounding *ADAMTS15*, likely resulting from homozygosity on recently configured haplotypes due to parental consanguinity. Inbreeding coefficients calculated from ES data confirmed known family histories of consanguinity (Table S4).

Adamts15 expression during embryogenesis

Using the MOCA database, we observed that *Adamts15* expression is mainly restricted to the mesenchyme (Fig. S4a). Therefore, we performed further characterization of the mesenchyme trajectory, which showed that most of the *Adamts15*-positive cells mapped to the connective tissue, skeletal muscle and chondrocyte trajectories (Fig. 2a).

In the developing limb, which is pathogenetically most relevant, *Adamts15* expression plateaued between E13.0 and E15.0 and disappeared almost completely by E15.5 (Fig. 2b). Also, in the developing limb most positive cells were mesenchymal, only few were of muscle or vascular origin (Fig. S4b). In order to gain insight into the cell types potentially affected by loss of *Adamts15*, we analyzed its co-expression with marker genes within the limb mesenchyme. While almost no co-expression was found for muscle, cartilage and joint interzone markers *Myh7*, *Acan* and *Gdf5*, versican (*Vcan*), one of the predicted substrates of *Adamts15*, was strongly co-expressed as well as *Fbn2* associated with an overlapping disorder (Fig. S4c). Moreover, significant overlaps were detected with *Osr1* and *Osr2*,

transcription factors expressed in muscle connective tissue, as well as the tendon markers *Scx* and *Tnmd* (Fig. 2c, S4b).

A whole mount *in situ* hybridization confirmed that *Adamts15* is expressed at perimuscular and peritendinous areas in the developing limbs (Fig. 2d). Additional RNAscope analysis corroborated the partial co-localization of *Adamts15* and *Osr1* (Fig. 2e). At E14.5, strong *Adamts15* signals were observed around tendons and at tendon attachment sites (Fig. 2f). These data indicate that the pathomechanism in this AR trait could involve muscle and tendon development.

Discussion

Our study identified four different homozygous variants in *ADAMTS15* in five individuals from four unrelated families that share similar rare disease traits. The phenotype is characterized by congenital contractures, primarily affecting the small joints of the fingers and toes. Additional features included contractures of the knee, Achilles tendon, spinal stiffness, scoliosis, and orthodontic abnormalities. Radiographic investigations excluded bony abnormalities of the affected joints. The sequence changes included an early nonsense variant: c.123C>G; p.(Tyr41*), a splice variant: c.1903-2A>G, and two missense variants: c.2281G>A; p.(Gly761Ser) and c.2715C>G; p.(Cys905Trp).

Interestingly, other ADAMTS superfamily members and direct interaction partners have been described in association with congenital contractures. Clinical features of *ADAMTS10*- and *ADAMTS17*- associated Weill-Marchesani-Syndrome Types 1 (WMS1; MIM: 277600) and 4 (WMS4; MIM: 613195) include short stature, microspherophakia, brachydactyly, thickened skin and joint stiffness of small and large joints.^{11,12} Besides strabismus, our affected participants did not show any additional ophthalmological features. Biallelic pathogenic variants of *ADAMTSL2* are associated with geleophysic dysplasia type 1 (GPHYSD1, MIM: 231050), a progressive musculoskeletal disorder characterized by severe short stature, brachydactyly, progressive joint contractures, cardiac valvular involvement and thickened skin.¹³ In contrast to WMS and GPHYSD1, the herein reported individuals do not consistently show skeletal anomalies, skin stiffening or pulmonary involvement. Compared to *FBN2*-associated congenital contractual arachnodactyly syndrome (CCA, MIM: 121050), also previously known as DA type 9, our participants did not display arachnodactyly, ear deformities or dolichostenomelia.¹⁴ A detailed list of the clinical features in our participants compared to the typical clinical findings of different types of WMS, *FBN2*-associated DA Type 9 (CCA) and GPHYSD1 is available in Table S2.

The variants identified here presumably result in an ADAMTS15 loss of function (LoF). Remarkably, no homozygous individuals for likely damaging predicted LoF variants are present in the gnomAD database (last access date 03/03/2022). The variant c.123C>G, p.(Tyr41*) in family A causes a PTC in the first exon and the intronic variant c.1903-2A>G leads to skipping of exon 7, resulting in a frameshift and PTC: p.(Val635Alafs*30). In both cases, the PTCs presumably result in nonsense-mediated decay (NMD) or a truncated protein, effectively deleting many functional domains. The missense variant p.(Gly761Ser) in family C affects a highly conserved amino acid residue within the ADAMTS spacer

region, while the missense variant in Family D p.(Cys905Trp) localizes to the second thrombospondin type 1 repeat. Notably, a variant at a homologous position in *ADAMTS13* p.(Cys1024Gly) is listed as pathogenic in ClinVar (ID: 5803). Analysis of ES-derived AOH/ROH data revealed, that the ultra-rare variants are located within long-sized runs of ROH, further supporting the Clan Genomics hypothesis.¹⁵ The AR inheritance and presence of two likely LoF alleles as the underlying disease mechanism are compatible with enzymatic disease and the thus far reported spectrum of pathogenic variants in the ADAMTS family members.⁸

In general, our understanding of the biological mechanisms of ECM regulation by ADAMTS proteoglycanases is only emerging and essentially depend on their substrates and other ECM-binding partners.¹⁶ ADAMTS15 is one of seven members (ADAMTS1, -4, -5, -8, -9, -15 and -20) that belong to an evolutionary distinct subset of proteoglycanases that are implicated in versican turnover.^{17,18} Since the other members of the ADAMTS/L superfamily that are already associated with joint contractures play a pivotal role in fibrillin microfibril assembly and ECM-associated signaling pathways (TGF- β , BMP), a functional interaction between these members and ADAMTS15 seems plausible and parsimoniously explains the aggregate data.

Analysis of cell lines frequently used for functional *in vitro* investigations indicated a surprising restriction of *ADAMTS15* expression. This was corroborated by single-cell sequencing data of whole mouse embryos showing an expression in the mouse limb only between E11.5 and E15.0. During this developmental phase, mesenchymal condensations of the skeletal elements are converted into cartilage and endochondral ossification begins.¹⁹ In parallel, the musculotendinous apparatus develops and tendon-bone connections are formed. While in the whole embryo *Adamts15* expression is partially found also in chondrocytes and muscle cells, in the limb the strongest co-expression is with the tendon marker *scleraxis* (*Scx*), the perimuscular connective tissue marker *Osr1* and with versican (*Vcan*). The latter co-expression is in line with the suggested function of *Adamts15* as a versicanase, although co-expression is not conclusive evidence for enzyme function.⁹ A direct role of *Adamts15* in the fusion of myoblasts was suggested based on expression analysis in C2C12 cells but has never been experimentally proven.¹⁸ The expression data presented here does not indicate significant expression in muscle cells. Co-expression with *Osr1* and *Scx* suggests a role of *Adamts15* in the formation of perimuscular connective tissue and tendons. Since depletion of *Osr1* in the limb leads to abnormal skeletal muscle development through altered ECM production, the loss of *ADAMTS15* might also have a similar, non-cell autonomous effect on muscle cells.²⁰

In conclusion, these studies describe a new rare syndrome with a distal arthrogyrosis phenotype that is associated with biallelic pathogenic variants in *ADAMTS15*. Due to the clinical features and the fact that ADAMTS15 belongs to the ADAMTS/L family, we would classify this disease trait as a novel connective-tissue related DA type. We hypothesize that impaired ADAMTS15 function causes tissue specific ECM dysregulation. Further experimental investigations are necessary to identify these tissue-specific molecular mechanisms.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We are grateful to the families for their participation in this study. We thank Aris. N. Economides and Manuel Holtgrewe for their valuable suggestions and support. JRL laboratory is supported by the United States (US) National Institutes of Neurological Disorders and Stroke (NINDS; R35 NS 105078), and in part by the U.S. National Human Genome Research Institute (NHGRI) and National Heart Lung and Blood Institute (NHBLI) to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG, UM1 HG006542), the National Institute of General Medical Sciences (NIGMS; R01 GM106373), the NHGRI Baylor College of Medicine Genomics Research Elucidates Genetics of Rare disease (BCM-GREGoR; U01 HG011758), the Muscular Dystrophy Association (MDA) (512848), and the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) of the National Institutes of Health under Award Number P50HD103555 for use of the Clinical Translation Core facilities. D.P. is supported by International Rett Syndrome Foundation (IRSF grant #3701-1). J.E.P. was supported by NHGRI K08 HG008986. U.K. obtained funding from the German Research Council (DFG) (KO 2891/9-1) and the BIH Center for Regenerative Therapies (BCRT)(cross-field project GenoPro).

Data Availability

Data supporting this paper are contained within the article and Supplementary information. Any additional data not compromised by ethical issues will be available upon request.

References:

1. Bamshad M, Van Heest AE, Pleasure D. Arthrogyrosis: a review and update. *J Bone Joint Surg Am.* 2009;91 Suppl 4:40–46.
2. Dahan-Oliel N, Cachecho S, Barnes D, et al. International multidisciplinary collaboration toward an annotated definition of arthrogyrosis multiplex congenita. *Am J Med Genet C Semin Med Genet.* 2019;181(3):288–299. [PubMed: 31282072]
3. Pehlivan D, Bayram Y, Gunes N, et al. The Genomics of Arthrogyrosis, a Complex Trait: Candidate Genes and Further Evidence for Oligogenic Inheritance. *Am J Hum Genet.* 2019;105(1):132–150. [PubMed: 31230720]
4. Whittle J, Johnson A, Dobbs MB, Gurnett CA. Models of Distal Arthrogyrosis and Lethal Congenital Contracture Syndrome. *Genes (Basel).* 2021;12(6).
5. Hall JG, Kimber E, Dieterich K. Classification of arthrogyrosis. *Am J Med Genet C Semin Med Genet.* 2019;181(3):300–303. [PubMed: 31271512]
6. Apte SS. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. *J Biol Chem.* 2009;284(46):31493–31497. [PubMed: 19734141]
7. Hubmacher D, Apte SS. ADAMTS proteins as modulators of microfibril formation and function. *Matrix Biol.* 2015;47:34–43. [PubMed: 25957949]
8. Rim JH, Choi YJ, Gee HY. Genomic Landscape and Mutational Spectrum of ADAMTS Family Genes in Mendelian Disorders Based on Gene Evidence Review for Variant Interpretation. *Biomolecules.* 2020;10(3).
9. Dancevic CM, Fraser FW, Smith AD, Stupka N, Ward AC, McCulloch DR. Biosynthesis and expression of a disintegrin-like and metalloproteinase domain with thrombospondin-1 repeats-15: a novel versican-cleaving proteoglycanase. *J Biol Chem.* 2013;288(52):37267–37276. [PubMed: 24220035]
10. Cao J, Spielmann M, Qiu X, et al. The single-cell transcriptional landscape of mammalian organogenesis. *Nature.* 2019;566(7745):496–502. [PubMed: 30787437]
11. Morales J, Al-Sharif L, Khalil DS, et al. Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature. *Am J Hum Genet.* 2009;85(5):558–568. [PubMed: 19836009]

12. Dagoneau N, Benoist-Lasselin C, Huber C, et al. ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. *Am J Hum Genet.* 2004;75(5):801–806. [PubMed: 15368195]
13. Le Goff C, Morice-Picard F, Dagoneau N, et al. ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. *Nat Genet.* 2008;40(9):1119–1123. [PubMed: 18677313]
14. Callewaert BL, Loeys BL, Ficcadenti A, et al. Comprehensive clinical and molecular assessment of 32 probands with congenital contractural arachnodactyly: report of 14 novel mutations and review of the literature. *Hum Mutat.* 2009;30(3):334–341. [PubMed: 19006240]
15. Lupski JR, Belmont JW, Boerwinkle E, Gibbs RA. Clan genomics and the complex architecture of human disease. *Cell.* 2011;147(1):32–43. [PubMed: 21962505]
16. Apte SS. ADAMTS Proteins: Concepts, Challenges, and Prospects. *Methods Mol Biol.* 2020;2043:1–12. [PubMed: 31463898]
17. McCulloch DR, Nelson CM, Dixon LJ, et al. ADAMTS metalloproteases generate active versican fragments that regulate interdigital web regression. *Dev Cell.* 2009;17(5):687–698. [PubMed: 19922873]
18. Stupka N, Kintakas C, White JD, et al. Versican processing by a disintegrin-like and metalloproteinase domain with thrombospondin-1 repeats proteinases-5 and -15 facilitates myoblast fusion. *J Biol Chem.* 2013;288(3):1907–1917. [PubMed: 23233679]
19. Rafipay A, Berg ALR, Erskine L, Vargesson N. Expression analysis of limb element markers during mouse embryonic development. *Developmental Dynamics.* 2018;247(11):1217–1226. [PubMed: 30225906]
20. Vallecillo-Garcia P, Orgeur M, Vom Hofe-Schneider S, et al. Odd skipped-related 1 identifies a population of embryonic fibro-adipogenic progenitors regulating myogenesis during limb development. *Nat Commun.* 2017;8(1):1218. [PubMed: 29084951]




Figure 1. Pedigrees, structure of ADAMTS15 protein and location of the identified variants and clinical features of individuals with biallelic variants in ADAMTS15.

(a) Pedigrees of the four consanguineous families included in this study. Affected and unaffected individuals are indicated by filled and open squares (males) and circles (females).

(b) Identified variants and schematic overview of their location within the ADAMTS15 protein. Red arrows point to the locations of the four variants identified within this study. TSP = thrombospondin type 1 domain.

(c) Clinical pictures and radiographs of affected individuals 1-5, all showing congenital flexion contractures of the interphalangeal joints and hypoplastic or absent palmar creases. Additional pictures of individual 1 (family A):

II-1) (bottom row) show a close-up to highlight the reduction of palmar creases and flexion contractures of the toes. Radiographs of the hands and feet indicate absence of any bony abnormalities that could explain the stiffening of the affected joints. Mild appearance of fetal finger pads and clinodactyly of the fifth finger were present in all affected individuals.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. Expression of *Adamts15* RNA during mouse embryonic development.

(a) Whole mouse embryo single-cell analysis of mesenchymal cells showing *Adamts15* expression. The strongest accumulation of positive cells was found in the connective tissue (c.t.) trajectory. (b) Single-cell analysis of *Adamts15*-expressing cells among mesenchymal cells in the developing limbs. Highest expression was found between E13.0 and E15.0. (c) Co-expression of *Adamts15* and marker genes *Scx* and *Osr1* RNA in cells from developing limbs. Colored numbers correspond to cells displaying expression for the respective gene, black numbers indicate double positive cells. (d) Whole mount in situ hybridization (WISH) for *Adamts15* in developing limbs at E12.5 and E13.5. Note perimuscular and -tendinous expression pattern at E13.5. (e) RNAscope co-labeling of *Adamts15* (green) and *Osr1* (white) in the distal limb at E13.5. Scale bar = 200 μ m. (f) In situ hybridization (ISH) for *Adamts15* in E14.5 forelimb in comparison to pan-MyHC immunostaining (red) for muscles and DAPI (blue) for nuclei on the same section. Inserts show muscle-tendon connection and arrowheads indicate tendon attachment sites at digits. Scale bar = 400 μ m. ch =

chondrocytes, c.m. = cardiac muscle, c.t. = connective tissue, i.m. = intermediate mesoderm, l.m. = limb mesenchyme, ob = osteoblasts, s.m. = skeletal muscle, t = tendon.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript